Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD
March 27, 2019 07:00 ET | Orchard Therapeutics Limited
Compared to Natural History, Late Infantile Patients Demonstrated Gross Motor Function Scores Higher by 65 and 72 Percentage Points at 2- and 3-Years Post Gene Therapy; Early Juvenile Patients...
Orchard Therapeutics Reports 2018 Financial Results and Reviews Recent Business Highlights
March 21, 2019 07:00 ET | Orchard Therapeutics Limited
Three Lead Programs for MLD, ADA-SCID and WAS on Track for Regulatory Filings Over the Next Three Years, with MLD and ADA-SCID Expected in 2020 Registrational Data Showing 100% Overall Survival and...
Orchard Therapeutics Strengthens Global Manufacturing and Supply Chain Leadership with Appointment of Ran Zheng as Chief Technical Officer
March 18, 2019 07:00 ET | Orchard Therapeutics Limited
BOSTON AND LONDON, March 18, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics to Webcast Conference Call of 2018 Financial Results on March 21, 2019
March 14, 2019 07:00 ET | Orchard Therapeutics Limited
BOSTON and LONDON, March 14, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Announces Acceptance of OTL-200 Abstract for MLD at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT)
March 11, 2019 07:00 ET | Orchard Therapeutics Limited
BOSTON and LONDON, March 11, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics to Present at the Cowen 39th Annual Health Care Conference on March 11, 2019
March 04, 2019 07:00 ET | Orchard Therapeutics Limited
BOSTON and LONDON, March 04, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Presents Clinical Proof-of-Concept Data for OTL-102 for the Treatment of X-CGD
February 25, 2019 07:30 ET | Orchard Therapeutics Limited
Six Patients Continue to Show Sustained Levels of Functioning Neutrophils After 12 Months and No Longer Receive Treatment with CGD-related Prophylactic Antibiotics Regulatory Discussions on...
Orchard Therapeutics Presents Two-Year Follow-Up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID
February 22, 2019 08:30 ET | Orchard Therapeutics Limited
100% Overall Survival and 100% Event Free Survival in Patients Treated with OTL-101 Compared to 88% OS and 56% EvFS with Historical HSCT Overall at 24 months Biologics License Application Submission...
Orchard Therapeutics Announces Acceptance of Late-Breaking Abstracts of OTL-101 for ADA-SCID and OTL-102 for X-CGD at the 2019 Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR
February 06, 2019 07:30 ET | Orchard Therapeutics Limited
BOSTON and LONDON, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with...
Orchard Therapeutics Appoints Industry Veteran Alicia Secor to its Board of Directors
December 07, 2018 07:30 ET | Orchard Therapeutics Limited
BOSTON and LONDON, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of...